These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 33984179)
1. Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study. Gustavsson A; Raket LL; Lilja M; Rutten-Jacobs L; Fues Wahl H; Bagijn M; Stomrud E; Hansson O; Palmqvist S Alzheimers Dement; 2021 Nov; 17(11):1832-1842. PubMed ID: 33984179 [TBL] [Abstract][Full Text] [Related]
2. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
3. Amyloid pathology in the progression to mild cognitive impairment. Insel PS; Hansson O; Mackin RS; Weiner M; Mattsson N; Neurobiol Aging; 2018 Apr; 64():76-84. PubMed ID: 29353101 [TBL] [Abstract][Full Text] [Related]
4. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
5. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies. Rådestig MA; Skoog J; Zetterberg H; Kern J; Zettergren A; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S J Alzheimers Dis; 2021; 79(1):225-235. PubMed ID: 33216028 [TBL] [Abstract][Full Text] [Related]
11. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study. Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084 [TBL] [Abstract][Full Text] [Related]
12. The implications of different approaches to define AT(N) in Alzheimer disease. Mattsson-Carlgren N; Leuzy A; Janelidze S; Palmqvist S; Stomrud E; Strandberg O; Smith R; Hansson O Neurology; 2020 May; 94(21):e2233-e2244. PubMed ID: 32398359 [TBL] [Abstract][Full Text] [Related]
13. Toxic Amyloid-β42 Conformer May Accelerate the Onset of Alzheimer's Disease in the Preclinical Stage. Futamura A; Hieda S; Mori Y; Kasuga K; Sugimoto A; Kasai H; Kuroda T; Yano S; Tsuji M; Ikeuchi T; Irie K; Ono K J Alzheimers Dis; 2021; 80(2):639-646. PubMed ID: 33579852 [TBL] [Abstract][Full Text] [Related]
14. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
15. A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease. Senda M; Ishii K; Ito K; Ikeuchi T; Matsuda H; Iwatsubo T; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikari Y; Niimi Y; Arai H; Tamaoka A; Arahata Y; Itoh Y; Tachibana H; Ichimiya Y; Washizuka S; Odawara T; Ishii K; Ono K; Yokota T; Nakanishi A; Matsubara E; Mori H; Shimada H J Prev Alzheimers Dis; 2021; 8(4):495-502. PubMed ID: 34585225 [TBL] [Abstract][Full Text] [Related]
16. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW; Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643 [TBL] [Abstract][Full Text] [Related]
17. Recognition Memory Performance as a Cognitive Marker of Prodromal Alzheimer's Disease. Goldstein FC; Loring DW; Thomas T; Saleh S; Hajjar I J Alzheimers Dis; 2019; 72(2):507-514. PubMed ID: 31594225 [TBL] [Abstract][Full Text] [Related]
18. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028 [TBL] [Abstract][Full Text] [Related]
19. Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials? Grill JD; Nuño MM; Gillen DL; Alzheimer Dis Assoc Disord; 2019; 33(2):104-112. PubMed ID: 30958413 [TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]